Today: 9 June 2026
Ondas Holdings stock rises on Jan. 16 investor day plan, SEC resale filing sharpens focus on 2026 outlook
5 January 2026
2 mins read

Ondas Holdings stock rises on Jan. 16 investor day plan, SEC resale filing sharpens focus on 2026 outlook

New York, January 5, 2026, 13:05 (ET) — Regular session

  • Ondas shares rose as the company set a Jan. 16 investor day focused on its autonomous systems unit and 2026 outlook.
  • A separate SEC filing registered 2.39 million shares for resale by existing holders tied to a prior subsidiary securities exchange.
  • Traders are watching whether the stock can hold above $11 after a volatile run and ahead of the Jan. 16 event.

Shares of Ondas Holdings Inc (ONDS.O) rose 6.5% to $11.74 in early afternoon trade on Monday after the company set a January 16 investor day and disclosed an SEC resale registration tied to its autonomous systems business.

The investor day matters because Ondas said it expects to lay out an updated 2026 business plan and a financial outlook, including revenue-growth assumptions and investment priorities. That is the next hard catalyst for a stock that has been driven by event risk and incremental disclosures rather than a steady earnings cadence.

The second catalyst is a prospectus supplement — an SEC document that registers shares so existing holders can resell them — covering 2,389,203 shares issued in an exchange involving securities at Ondas Autonomous Systems (OAS), a subsidiary. The company is not selling stock in that filing, but the registration can make it easier for those holders to sell into the market over time.

Ondas said the January 16 virtual event will focus primarily on OAS and include a question-and-answer session with senior management. The company said it will discuss its “Core+ Strategic Growth Program,” capital allocation framework and progress toward improved operating leverage — a measure of how margins can expand as revenue grows. SEC

In the prospectus supplement, Ondas said the shares were issued to “selling stockholders” who elected to defer closing to January 5, after the company issued 5,299,482 shares on December 27 under related exchange agreements. The filing said those stockholders are subject to a daily trading-volume limit set at 5% of the stock’s 10-day average daily volume. Ondas Holdings Inc.

The same document said the underlying exchange traces back to 2024 OAS notes and warrants held by a private investor group that included Privet Ventures LLC, an entity affiliated with Eric Brock, Ondas’ chairman and CEO. After the exchange, Ondas said it owns about 99% of OAS on a fully diluted basis.

Ondas has also been repositioning its corporate profile. In a January 2 press release, Brock said the company now operates as “a scaled, global defense and security technology platform,” and that a planned name change to Ondas Inc. is meant to align its identity with that shift. Ondas Holdings Inc.

On the tape, Ondas traded between $11.01 and $11.81 on Monday, with about 71 million shares changing hands by early afternoon, according to market data. Traders have treated $11 as the near-term line to hold, with the session high around $11.80 the first upside level.

But the setup carries risk. A resale registration can become an overhang if selling accelerates, and the January 16 presentation raises the bar for management’s 2026 assumptions on demand, spending and scaling — areas where any miss can reverse momentum quickly.

Next up is Ondas’ OAS Investor Day on January 16 at 10:00 a.m. ET, where investors will be looking for specific 2026 targets, capital needs and timing on margin improvement — and for any sign that registered holders are beginning to sell into strength.

Stock Market Today

  • Wall Street Eyes Modest Gains as AI Stocks Rebound, Oil Prices Decline
    June 9, 2026, 10:03 AM EDT. Wall Street opened higher Tuesday with the S&P 500 climbing 0.6%, nearing its all-time high. The tech-heavy Nasdaq rose 0.7%, led by AI-related chipmakers like Micron Technology, which rebounded after recent sharp losses. Meanwhile, oil prices slipped, with Brent crude falling 1.6% to $92.83 a barrel amid easing geopolitical tensions. The decline in fuel costs boosted major U.S. airlines, which face soaring jet fuel expenses. Elevated oil prices continue to drive inflation and push yields higher, with the 10-year U.S. Treasury yield near 4.55%. Ahead this week, U.S. inflation data and a Federal Reserve policy meeting are in focus amid expectations of steady or higher interest rates. The mixed signals reflect ongoing uncertainty in markets amid global conflicts and inflation pressures.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
NuScale Power stock jumps 16% as House sets ‘New Nuclear Era’ hearing — what’s next for SMR
Previous Story

NuScale Power stock jumps 16% as House sets ‘New Nuclear Era’ hearing — what’s next for SMR

3.5 million hit by University of Phoenix data breach as school rolls out “credit for prior learning” push
Next Story

3.5 million hit by University of Phoenix data breach as school rolls out “credit for prior learning” push

Go toTop